GNLX GENELUX CORP

Genelux Corporation Announces Upcoming Virtual Fireside Chat Hosted by Titan Partners

Genelux Corporation Announces Upcoming Virtual Fireside Chat Hosted by Titan Partners

WESTLAKE VILLAGE, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO and Chairman of the Board; Matt Pulisic, Chief Financial Officer; and Dr. Jason Litten, Chief Medical Officer, will participate in a virtual fireside chat hosted by Boris Peaker, PhD, Managing Director and Senior Equity Research Analyst at Titan Partners, on Monday, January 19, 2026 at 9:00 a.m. PT.

A live webcast of the fireside chat can be found and on the investor relations section of the Company’s website at . Following the live webcast, an archived replay will be available on the Company’s website.

About Genelux Corporation

Genelux is a late clinical-stage biopharmaceutical company focused on developing next-generation oncolytic immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Olvi-Vec currently is being evaluated in two U.S.-based clinical trials: OnPrime/GOG-3076, a multi-center, randomized, open-label Phase 3 registrational trial evaluating the efficacy and safety of Olvi-Vec in combination platinum-doublet + bevacizumab compared with physician's choice of chemotherapy and bevacizumab in patients with platinum-resistant/refractory ovarian cancer; and VIRO-25, a multi-center, randomized, open-label Phase 2 trial evaluating the efficacy and safety of Olvi-Vec & platinum-doublet + physician's choice of immune checkpoint inhibitor compared to docetaxel in non-small-cell lung cancer. Additionally, Olvi-Vec currently is being evaluated for dose selection in Olvi-Vec-SCLC-202, a China-based, multi-center, open label Phase 1b/2 trial evaluating the efficacy and safety of Olvi-Vec & platinum-doublet in recurrent small-cell lung cancer. The core of Genelux's discovery and development efforts revolves around its proprietary CHOICE™ platform from which Genelux has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec.

Investor Contact

Austin Murtagh

Precision AQ

Media Contact

Ashley Murphy

Precision AQ

Source: Genelux Corporation



EN
12/01/2026

Underlying

GNLXGENELUX CORP

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on GENELUX CORP

 PRESS RELEASE
Free
GNLX GENELUX CORP

Genelux Corporation Announces Upcoming Virtual Fireside Chat Hosted by...

Genelux Corporation Announces Upcoming Virtual Fireside Chat Hosted by Titan Partners WESTLAKE VILLAGE, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO and Chairman of the Board; Matt Pulisic, Chief Financial Officer; and Dr. Jason Litten, Chief Medical Officer, will participate in a virtual fireside chat hosted by Boris Peaker, PhD, Managing Director and Senior Equity Research Analyst at Titan Partners, on Monday, January 19, 2026 at 9:00 a.m. PT. A live webcast of the fireside ...

January 12, 2026 1 EN
 PRESS RELEASE
Free
GNLX GENELUX CORP

Genelux Corporation Announces Pricing of $20.0 Million Underwritten Pu...

Genelux Corporation Announces Pricing of $20.0 Million Underwritten Public Offering of Common Stock WESTLAKE VILLAGE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation (“Genelux”) (Nasdaq: GNLX), a late clinical-stage immuno-oncology company, today announced the pricing of an underwritten public offering of 6,666,667 shares of its common stock at a price to the public of $3.00 per share. All of the shares in the offering are to be sold by Genelux. The gross proceeds to Genelux from the offering are expected to be approximately $20.0 million, before deducting underwriting disc...

January 8, 2026 1 EN
 PRESS RELEASE
Free
GNLX GENELUX CORP

Genelux Corporation Announces Proposed Public Offering of Common Stock

Genelux Corporation Announces Proposed Public Offering of Common Stock WESTLAKE VILLAGE, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation (“Genelux”) (Nasdaq: GNLX), a late clinical-stage immuno-oncology company, today announced that it has commenced a proposed underwritten public offering of its common stock. In addition, Genelux expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the number of shares of common stock sold in connection with the proposed offering. All shares are being offered by Genelux. The proposed offering is subject to ...

January 7, 2026 1 EN
 PRESS RELEASE
Free
GNLX GENELUX CORP

Genelux Corporation Reports Encouraging Interim Data of Systemic Admin...

Genelux Corporation Reports Encouraging Interim Data of Systemic Administration of Olvi-Vec in Ongoing Lung Cancer Trials -- Interim data from 14 patients with progressive lung cancers in dose-escalation cohorts of systemically administered Olvi-Vec-primed immunochemotherapy across ongoing SCLC and NSCLC trials; enrollment ongoing – -- In platinum-relapsed or platinum-refractory advanced SCLC, two of three partial responses (PRs) occurred in the highest dose cohort tested as of the data review cutoff date (tumor shrinkage of ~55% and ~85%), with three PRs out of nine subjects (33%) across ...

January 5, 2026 1 EN
 PRESS RELEASE
Free
GNLX GENELUX CORP

Genelux Corporation Announces Appointment of Jason Litten, M.D., as Ch...

Genelux Corporation Announces Appointment of Jason Litten, M.D., as Chief Medical Officer WESTLAKE VILLAGE, Calif., Jan. 02, 2026 (GLOBE NEWSWIRE) --   NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced the appointment of Jason Litten, M.D., as Chief Medical Officer, effective January 2, 2026. Dr. Litten will oversee all clinical development and medical strategy as the company advances Olvi-Vec through multiple upcoming pivotal milestones. “We are excited to welcome Jason, who is widely recognized for his strategic approach to clinical development and commitm...

January 2, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch